PMID- 38111444 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240213 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 11 DP - 2023 Nov TI - Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population. PG - e48994 LID - 10.7759/cureus.48994 [doi] LID - e48994 AB - BACKGROUND AND AIM: While proton pump inhibitor (PPI) therapy has proven to be effective in managing gastroesophageal reflux disease (GERD), a notable portion of patients who experience GERD symptoms may not respond to this treatment. Research suggests that roughly 30% of individuals with a presumed GERD diagnosis may continue to experience symptoms, whether partially or completely, even when receiving PPI therapy. The aim of this study was to assess the treatment of gastrointestinal diseases with a novel potassium-competitive acid blocker (P-CAB), vonoprazan, in terms of its effectiveness and safety in the Pakistani population. METHODS: This prospective, multicenter, observational study was conducted in Pakistan. This study included 1,642 patients from January 2023 to August 2023, aged 18 years, with gastrointestinal disorders. All demographic data, medical history, GERD severity assessment questionnaire (GerdQ), and laboratory parameters, including stool assessment for Helicobacter pylori (H. pylori), were observed. Patients were orally treated with vonoprazan at doses of 10 mg or 20 mg, once or twice daily. Statistical analysis was done by one-way ANOVA. RESULTS: Out of 1,642 patients, 840 (51.2%) were males and 802 (48.8%) were females, with a mean age of 39.81+/-14.61 years. The mean GerdQ score at baseline was 20.37+/-15.87, 7.24+/-8.15 at the second week of treatment, and 3.70+/-6.31 at the fourth week of treatment (p<0.001). 90.74% of patients achieved H. pylori eradication. Most patients were acid regurgitation and heartburn-free for >70% of days. Most of the patients, 1,283 (78.13%), exhibited good treatment compliance. Mild adverse events were reported in 37 (2.3%) patients. CONCLUSIONS: The use of vonoprazan significantly reduced the likelihood of GERD by improving symptoms and was also highly effective in the elimination of H. pylori infections. Vonoprazan was generally well tolerated. CI - Copyright (c) 2023, Abbasi et al. FAU - Abbasi, Amanullah AU - Abbasi A AD - Internal Medicine, Civil Hospital Karachi, Karachi, PAK. FAU - Siddiqui, Shajee Ahmad AU - Siddiqui SA AD - Internal Medicine, Pakistan Institute of Medical Sciences, Islamabad, PAK. FAU - Ram, Bikha AU - Ram B AD - Internal Medicine, Liaquat University of Medical and Health Sciences, Hyderabad, PAK. FAU - Khan, Jibran Umar Ayub AU - Khan JUA AD - Internal Medicine, Kabir Medical College, Peshawar, PAK. FAU - Sheikh, Khalid AU - Sheikh K AD - Internal Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK. FAU - Ali, Asif AU - Ali A AD - Internal Medicine, Civil Hospital Karachi, Karachi, PAK. AD - Medicine, Dow General Hospital/Dow University of Health Sciences, Karachi, PAK. FAU - Raja Memon, Waseem AU - Raja Memon W AD - Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK. FAU - Rehan, Muhammad AU - Rehan M AD - Medicine, Civil Hospital Karachi, Karachi, PAK. FAU - Zia Ul Haq, Muhammad AU - Zia Ul Haq M AD - Medicine, Sir Ganga Ram Hospital, Lahore, PAK. FAU - Kumar Seetlani, Naresh AU - Kumar Seetlani N AD - Internal Medicine, Civil Hospital Karachi, Karachi, PAK. FAU - Akhter, Tayyab S AU - Akhter TS AD - Gastroenterology, Holy Family Hospital, Islamabad, PAK. FAU - Khoso, Masood AU - Khoso M AD - Gastroenterology, Jinnah Postgraduate Medical Center, Karachi, PAK. FAU - Javed, Asif AU - Javed A AD - Internal Medicine, Social Security New Born & Children Hospital (MNCH), Faisalabad, PAK. FAU - Hussain Khokhar, Riaz AU - Hussain Khokhar R AD - Internal Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK. FAU - Hussain Memon, Zaheer AU - Hussain Memon Z AD - Internal Medicine, Suleman Roshan Medical College, Tandoadam, PAK. FAU - Akbar, Wajid AU - Akbar W AD - Internal Medicine, Bacha Khan Medical College, Peshawar, PAK. FAU - Naeem, M AU - Naeem M AD - Gastroenterology, Mardan Medical Complex, Peshawar, PAK. FAU - Shaikh, Samiullah AU - Shaikh S AD - Internal Medicine, Gijal Mao M/c Qasimabad, Hyderabad, PAK. FAU - Khan Khattak, Abbas AU - Khan Khattak A AD - Gastroenterology, Abyseen Plaza Dabgari, Peshawar, PAK. FAU - Memon, A Qayoom AU - Memon AQ AD - Gastroenterology, Private Clinic, Nawabshah, PAK. FAU - Bhatty, Shaheen AU - Bhatty S AD - Internal Medicine, Dr. Ruth K. M. Pfau Civil Hospital, Karachi, PAK. FAU - Sultan, Omar AU - Sultan O AD - Internal Medicine, Jinnah Postgraduate Medical Center, Karachi, PAK. FAU - Shani, Idress AU - Shani I AD - Internal Medicine, District Head Quarters (DHQ) Hospital, Faisalabad, PAK. FAU - Maheshwary, Neeta AU - Maheshwary N AD - Head Medical Affairs, Helix Pharma Pvt Ltd, Karachi, PAK. LA - eng PT - Journal Article DEP - 20231118 PL - United States TA - Cureus JT - Cureus JID - 101596737 EIN - Cureus. 2023 Dec 6;15(12):c147. PMID: 38347864 PMC - PMC10726382 OTO - NOTNLM OT - acid control OT - dyspepsia OT - gastroesophageal reflux disease OT - helicobacter pylori OT - vonoprazan COIS- The authors have declared financial relationships, which are detailed in the next section. EDAT- 2023/12/19 06:42 MHDA- 2023/12/19 06:43 PMCR- 2023/11/18 CRDT- 2023/12/19 03:46 PHST- 2023/11/14 00:00 [accepted] PHST- 2023/12/19 06:43 [medline] PHST- 2023/12/19 06:42 [pubmed] PHST- 2023/12/19 03:46 [entrez] PHST- 2023/11/18 00:00 [pmc-release] AID - 10.7759/cureus.48994 [doi] PST - epublish SO - Cureus. 2023 Nov 18;15(11):e48994. doi: 10.7759/cureus.48994. eCollection 2023 Nov.